Side-by-side comparison of AI visibility scores, market position, and capabilities
Zurich ETH Zurich spin-off DNA supply chain traceability (founded 2016); $1.5M 2024 revenue (+84%) tracking 30M+ garments for C&A/Soorty with forensic-grade origin verification competing with Applied DNA Sciences for EU textile compliance.
Haelixa is a Zurich, Switzerland-based physical supply chain traceability company — an ETH Zurich spin-off founded in 2016 by PhD researchers — embedding DNA markers into textiles, precious materials, and luxury goods to provide forensic-grade authentication and origin verification that remains detectable through washing, processing, manufacturing, and global distribution. Founded by Michela Puddu (CEO) and CTO Gediminas Mikutis, with new CEO Patrick Strumpf and Stefan Karlen joining the Board in 2024-2025, Haelixa has grown to 17 employees and achieved $1.5 million in 2024 revenue (up 84% from $815,000 in 2023), tracking over 30 million garments globally for partners including C&A, Soorty Enterprises, Oerlikon, Damteks, and regenagri. The company has raised seed funding from investiere and Zurich Cantonal Bank and won 20+ international awards. Haelixa's DNA markers are engineered to be non-toxic, vegan, and biodegradable — validated through laboratory spectroscopy analysis providing forensic-grade proof of origin.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.